Therapeutic Asset Ratings
220 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Ethiodized Oil
Gastric Cancer
Teclison Ltd.
P2
CCC
(48)
GELATIN PORCINE SKIN, FORMALIN TREATED
Gastric Cancer
Teclison Ltd.
P2
CCC
(48)
her3-dxd
Gastric Cancer
Daiichi Sankyo
P2
CCC
(48)
ibi310
Gastric Cancer
Peking University
P2
CCC
(48)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide
Gastric Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
P2
CCC
(48)
Navicixizumab
Gastric Cancer
OncXerna Theraputics, Inc.
P2
CCC
(48)
Pd-L1 T-Hank
Gastric Cancer
ImmunityBio, Inc.
P2
CCC
(48)
Penpulimab
Gastric Cancer
The Central Hospital of Lishui City
P2
CCC
(48)
PREDNISONE TABLETS
Gastric Cancer
AstraZeneca
P2
CCC
(48)
Rain-32
Gastric Cancer
Rain Oncology Inc
P2
CCC
(48)
Serplulimab
Gastric Cancer
RenJi Hospital
P2
CCC
(48)
Si-B003
Gastric Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
P2
CCC
(48)
Tirapazamine
Gastric Cancer
Teclison Ltd.
P2
CCC
(48)
Vebreltinib
Gastric Cancer
Apollomics Inc.
P2
CCC
(48)
Volrustomig
Gastric Cancer
AstraZeneca
P2
CCC
(48)
Tinengotinib
Gastric Cancer
TransThera Sciences (Nanjing), Inc.
P1/2
CCC
(48)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines.
Gastric Cancer
David Wald
P1/2
CC
(46)
Bms-907351
Gastric Cancer
Anwaar Saeed
P1/2
CC
(46)
Cea Car-T Cells
Gastric Cancer
Chongqing Precision Biotech Co., Ltd
P1/2
CC
(46)
Cea-Targeted Car-T
Gastric Cancer
Chongqing Precision Biotech Co., Ltd
P1/2
CC
(46)
T-Dxd
Gastric Cancer
Iambic Therapeutics, Inc
P1/2
CC
(46)
ab-201
Gastric Cancer
GC Cell Corporation
P1/2
CC
(45)
Capmatinib
Gastric Cancer
Cancer Research UK
P2/3
CC
(45)
Futibatinib
Gastric Cancer
Taiho Pharmaceutical Co., Ltd.
P1/2
CC
(45)
Polyiclc
Gastric Cancer
Mayo Clinic
P1/2
CC
(45)
Showing 51 to 75 of 220 assets
Previous
Page 3 of 9
Next